BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bioxel Pharma (BIP.V) Seeks to Reprice Warrants Issued in November 2007


9/10/2008 9:44:36 AM

QUEBEC CITY, QUEBEC--(Marketwire - September 10, 2008) - Bioxel Pharma Inc. (TSX VENTURE: BIP) a leading manufacturer of taxane active pharmaceutical ingredients (APIs) and developer of targeted oncology drugs, announced today that it is requesting the repricing of the exercise price of 25,993,750 warrants to $0.10 per common share from the initial exercise price of $0.16 and the extension of the expiry date to November 21, 2010 from November 21, 2009. The warrants were issued as part of the private placement by Bioxel on November 21, 2007 of convertible Debentures due 2014. Such repricing is subject to the approval of the TSX Venture Exchange and the warrantholders. Proceeds from any exercise of warrants will be used to continue funding the implementation of its commercial scale manufacturing capabilities for semi-synthetic docetaxel, for R&D and for working capital purposes.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES